Announcement • Jul 25
Lyka Labs Limited to Report Q1, 2027 Results on Aug 10, 2026 Lyka Labs Limited announced that they will report Q1, 2027 results on Aug 10, 2026 Reported Earnings • Jul 20
Full year 2026 earnings released: ₹2.81 loss per share (vs ₹2.22 profit in FY 2025) Full year 2026 results: ₹2.81 loss per share (down from ₹2.22 profit in FY 2025). Revenue: ₹1.25b (down 7.3% from FY 2025). Net loss: ₹100.3m (down 227% from profit in FY 2025). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • May 26
Full year 2026 earnings released: ₹2.81 loss per share (vs ₹2.22 profit in FY 2025) Full year 2026 results: ₹2.81 loss per share (down from ₹2.22 profit in FY 2025). Revenue: ₹1.32b (down 2.2% from FY 2025). Net loss: ₹100.3m (down 227% from profit in FY 2025). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • May 25
Lyka Labs Limited, Annual General Meeting, Aug 10, 2026 Lyka Labs Limited, Annual General Meeting, Aug 10, 2026. Announcement • May 12
Lyka Labs Limited to Report Q4, 2026 Results on May 25, 2026 Lyka Labs Limited announced that they will report Q4, 2026 results on May 25, 2026 New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹1.83b market cap, or US$19.6m). Reported Earnings • Jan 30
Third quarter 2026 earnings released: EPS: ₹0 (vs ₹0.75 in 3Q 2025) Third quarter 2026 results: EPS: ₹0 (down from ₹0.75 in 3Q 2025). Revenue: ₹318.9m (down 5.6% from 3Q 2025). Net loss: ₹3.0k (down 100% from profit in 3Q 2025). Profit margin: 0% (down from 8.0% in 3Q 2025). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Jan 15
Lyka Labs Limited to Report Q3, 2026 Results on Jan 29, 2026 Lyka Labs Limited announced that they will report Q3, 2026 results on Jan 29, 2026 Reported Earnings • Nov 13
Second quarter 2026 earnings released: ₹0.94 loss per share (vs ₹0.58 profit in 2Q 2025) Second quarter 2026 results: ₹0.94 loss per share (down from ₹0.58 profit in 2Q 2025). Revenue: ₹377.5m (down 8.3% from 2Q 2025). Net loss: ₹33.6m (down 260% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Oct 23
Lyka Labs Limited to Report Q2, 2026 Results on Nov 12, 2025 Lyka Labs Limited announced that they will report Q2, 2026 results on Nov 12, 2025 Announcement • Aug 01
Lyka Labs Limited Announces Resignation of Shekhar R Singh as A Company Secretary and Compliance Officer, Effective August 1, 2025 The board of diectors of Lyka Labs Limited at its meeting held on August 1, 2025 announced that the board took note of the resignation tendered by Mr. Shekhar R Singh as a Company Secretary and Compliance Officer vide letter dated 1st July, 2025 citing the reason to pursue an alternative career opportunity outside the organization. The resignation was effective from the close of business hours on 30th July, 2025. Mr. Shekhar R Singh has confirmed that he will continue to discharge all responsibilities, including those connected with the forthcoming 46th Annual General Meeting (AGM) and will ensure a smooth, structured handover before his exit. After due consideration, the Board accepted the resignation with effect from the close of business hours on the 1st August, 2025 . Announcement • Jul 21
Lyka Labs Limited to Report Q1, 2026 Results on Aug 01, 2025 Lyka Labs Limited announced that they will report Q1, 2026 results on Aug 01, 2025 Reported Earnings • Jul 10
Full year 2025 earnings released: EPS: ₹2.22 (vs ₹0.79 loss in FY 2024) Full year 2025 results: EPS: ₹2.22 (up from ₹0.79 loss in FY 2024). Revenue: ₹1.35b (up 27% from FY 2024). Net income: ₹79.0m (up ₹105.0m from FY 2024). Profit margin: 5.9% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Reported Earnings • May 28
Full year 2025 earnings released: EPS: ₹2.22 (vs ₹0.79 loss in FY 2024) Full year 2025 results: EPS: ₹2.22 (up from ₹0.79 loss in FY 2024). Revenue: ₹1.41b (up 33% from FY 2024). Net income: ₹80.1m (up ₹106.1m from FY 2024). Profit margin: 5.7% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • May 27
Lyka Labs Limited, Annual General Meeting, Aug 01, 2025 Lyka Labs Limited, Annual General Meeting, Aug 01, 2025. Announcement • May 14
Lyka Labs Limited to Report Q4, 2025 Results on May 26, 2025 Lyka Labs Limited announced that they will report Q4, 2025 results on May 26, 2025 Announcement • Apr 08
Lyka Labs Limited Secures Indian Patent for Pregabalin Gel 8% Lyka Labs Limited announced that it has been granted an Indian Patent for its proprietary product, Pregabalin Gel 8%, with patent protection valid through 2043. This significant milestone reinforces Lyka's focus on innovation and its leadership in developing topical drug delivery systems. Pregabalin Gel 8%, a topical formulation designed for the effective management of diabetic neuropathic pain, received regulatory approval from the Central Drugs Standard Control Organization in October 2024 for manufacturing and marketing in India. The product was officially launched in December 2024 by Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare under a P2P (Product-to-Product) license from Lyka Labs. This gel formulation represents a first-of-its-kind innovation in India, offering localized delivery of pregabalin directly at the site of pain, potentially minimizing systemic exposure and related side effects commonly associated with oral formulations. Lyka Labs has conducted clinical studies supporting the efficacy, safety, and patient convenience of Pregabaline Gel 8%, making it a promising alternative for millions suffering from chronic diabetic neuropathic conditions. With this patent, Lyka Labs strengthens its intellectual property portfolio and reaffirms its vision to be at the forefront of innovative pharmaceutical solutions. Reported Earnings • Feb 05
Third quarter 2025 earnings released: EPS: ₹0.75 (vs ₹0.53 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.75 (up from ₹0.53 in 3Q 2024). Revenue: ₹346.2m (up 6.3% from 3Q 2024). Net income: ₹27.1m (up 52% from 3Q 2024). Profit margin: 7.8% (up from 5.5% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance. Announcement • Dec 30
Lyka Labs Limited to Report Q3, 2025 Results on Feb 04, 2025 Lyka Labs Limited announced that they will report Q3, 2025 results on Feb 04, 2025 Announcement • Nov 13
Lyka Labs Limited Appoints Shekhar R Singh as Company Secretary & Compliance Officer Lyka Labs Limited at its board meeting held on November 12, 2024, has appointed Mr. Shekhar R Singh as a Company Secretary & Compliance Officer and designated as a Key Managerial Personnel of the Company with effect from 12th November, 2024. Educational Qualification: Member of the Institute of Company Secretaries; B.Com and LL.B from University of Mumbai; Post Graduate Diploma in Securities Law from Government Law Collage-Mumbai. Mr. Shekhar R Singh is a qualified Company Secretary and law graduate with 18 years of experience in legal and Company Secretarial functions. Reported Earnings • Nov 13
Second quarter 2025 earnings released: EPS: ₹0.58 (vs ₹0.16 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹0.58 (up from ₹0.16 loss in 2Q 2024). Revenue: ₹411.8m (up 47% from 2Q 2024). Net income: ₹21.0m (up ₹25.8m from 2Q 2024). Profit margin: 5.1% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. Announcement • Oct 23
Lyka Labs Limited to Report Q2, 2025 Results on Nov 12, 2024 Lyka Labs Limited announced that they will report Q2, 2025 results on Nov 12, 2024 New Risk • Aug 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.8x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (₹5.51b market cap, or US$65.6m). Announcement • Aug 02
Lyka Labs Limited to Report Q1, 2025 Results on Aug 09, 2024 Lyka Labs Limited announced that they will report Q1, 2025 results at 12:08 PM, Indian Standard Time on Aug 09, 2024 Reported Earnings • Jul 22
Full year 2024 earnings released: ₹0.79 loss per share (vs ₹4.63 loss in FY 2023) Full year 2024 results: ₹0.79 loss per share (improved from ₹4.63 loss in FY 2023). Revenue: ₹1.06b (up 19% from FY 2023). Net loss: ₹26.0m (loss narrowed 81% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Announcement • Jul 18
Lyka Labs Limited, Annual General Meeting, Aug 09, 2024 Lyka Labs Limited, Annual General Meeting, Aug 09, 2024, at 11:00 Indian Standard Time. Reported Earnings • May 22
Full year 2024 earnings released: ₹0.79 loss per share (vs ₹4.63 loss in FY 2023) Full year 2024 results: ₹0.79 loss per share (improved from ₹4.63 loss in FY 2023). Revenue: ₹1.13b (up 26% from FY 2023). Net loss: ₹24.9m (loss narrowed 81% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Announcement • May 12
Lyka Labs Limited to Report Q4, 2024 Results on May 21, 2024 Lyka Labs Limited announced that they will report Q4, 2024 results on May 21, 2024 Board Change • Feb 22
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Chairman of the Board Babulal Jain was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 09
Third quarter 2024 earnings released: EPS: ₹0.53 (vs ₹3.64 loss in 3Q 2023) Third quarter 2024 results: EPS: ₹0.53 (up from ₹3.64 loss in 3Q 2023). Revenue: ₹331.1m (up 86% from 3Q 2023). Net income: ₹17.8m (up ₹122.0m from 3Q 2023). Profit margin: 5.4% (up from net loss in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 62% per year, which means it is well ahead of earnings. Announcement • Feb 01
Lyka Labs Limited to Report Q3, 2024 Results on Feb 08, 2024 Lyka Labs Limited announced that they will report Q3, 2024 results on Feb 08, 2024 Reported Earnings • Nov 03
Second quarter 2024 earnings released: ₹0.16 loss per share (vs ₹0.14 loss in 2Q 2023) Second quarter 2024 results: ₹0.16 loss per share (further deteriorated from ₹0.14 loss in 2Q 2023). Revenue: ₹282.3m (up 11% from 2Q 2023). Net loss: ₹4.87m (loss widened 27% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 85% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Oct 21
Lyka Labs Limited to Report Q2, 2024 Results on Nov 02, 2023 Lyka Labs Limited announced that they will report Q2, 2024 results on Nov 02, 2023 Announcement • Oct 12
Lyka Labs Limited Receives Product Permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w Lyka Labs Limited announced that the Company has received the product permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w. The Company has received this permission after successfully completing the Clinical Trial on 125 patients across 8 Clinical Trial Centers within India. Announcement • Sep 27
Lyka Labs Limited Announces Cessation of Sandeep Parikh as Independent Director Lyka Labs Limited announced that Mr. Sandeep Parikh has completed his term as an Independent Director on September 25, 2023 and consequently ceased as the Independent Director of the Company from the end of day on September 25, 2023. Mr. Sandeep’s Membership of board committees: Audit Committee (Member), Nomination & Remuneration Committee (Member), Stakeholders Relationship Committee (Member), Corporate Social Responsibility Committee (Member). Mr. Sandeep Parikh automatically ceased as a Member of the aforesaid Committees in Lyka Labs Limited with effect from September 25, 2023. Announcement • Jul 28
Lyka Labs Limited to Report Q1, 2024 Results on Aug 02, 2023 Lyka Labs Limited announced that they will report Q1, 2024 results on Aug 02, 2023 Reported Earnings • Jul 14
Full year 2023 earnings released: ₹4.63 loss per share (vs ₹13.56 profit in FY 2022) Full year 2023 results: ₹4.63 loss per share (down from ₹13.56 profit in FY 2022). Revenue: ₹894.2m (down 52% from FY 2022). Net loss: ₹133.2m (down 134% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 78% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 12
Lyka Labs Limited, Annual General Meeting, Aug 02, 2023 Lyka Labs Limited, Annual General Meeting, Aug 02, 2023, at 11:00 Indian Standard Time. Agenda: To receive, consider and adopt the Standalone and Consolidated Audited Financial Statements along with Balance Sheet as at 31st March 2023, Statement of Profit and Loss Account and Cash Flow Statement for the year ended on that date and reports of Board of Directors and Auditors thereon; to appoint a Director in place of Mr. Prashant Godha, Non - Executive Director who retires by rotation and being eligible, offers himself for re-appointment; to consider the Approval of remuneration to the Cost Auditor for the financial year 2023-24; and to discuss other matters. Reported Earnings • May 24
Full year 2023 earnings released: ₹4.63 loss per share (vs ₹13.56 profit in FY 2022) Full year 2023 results: ₹4.63 loss per share (down from ₹13.56 profit in FY 2022). Revenue: ₹964.7m (down 48% from FY 2022). Net loss: ₹132.1m (down 134% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 19
Lyka Labs Limited to Report Q4, 2023 Results on May 23, 2023 Lyka Labs Limited announced that they will report Q4, 2023 results on May 23, 2023 Reported Earnings • Feb 08
Third quarter 2023 earnings released: ₹3.64 loss per share (vs ₹2.11 profit in 3Q 2022) Third quarter 2023 results: ₹3.64 loss per share (down from ₹2.11 profit in 3Q 2022). Revenue: ₹188.8m (down 47% from 3Q 2022). Net loss: ₹104.2m (down 271% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has increased by 84% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 01
Lyka Labs Limited to Report Q3, 2023 Results on Feb 07, 2023 Lyka Labs Limited announced that they will report Q3, 2023 results on Feb 07, 2023 Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Chairman of the Board Babulal Jain was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Nov 11
Second quarter 2023 earnings released: ₹0.14 loss per share (vs ₹9.90 profit in 2Q 2022) Second quarter 2023 results: ₹0.14 loss per share (down from ₹9.90 profit in 2Q 2022). Revenue: ₹267.2m (down 64% from 2Q 2022). Net loss: ₹3.84m (down 101% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has increased by 94% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Sep 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Additional Director Prashant Godha was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improved over the past week After last week's 18% share price gain to ₹138, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 770% over the past three years. Reported Earnings • Jul 14
Full year 2022 earnings released: EPS: ₹13.57 (vs ₹4.07 loss in FY 2021) Full year 2022 results: EPS: ₹13.57 (up from ₹4.07 loss in FY 2021). Revenue: ₹1.94b (up 183% from FY 2021). Net income: ₹390.0m (up ₹506.6m from FY 2021). Profit margin: 20% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has increased by 82% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 22
Full year 2022 earnings released: EPS: ₹13.57 (vs ₹4.07 loss in FY 2021) Full year 2022 results: EPS: ₹13.57 (up from ₹4.07 loss in FY 2021). Revenue: ₹1.96b (up 186% from FY 2021). Net income: ₹390.0m (up ₹506.6m from FY 2021). Profit margin: 20% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year whereas the company’s share price has increased by 74% per year. Valuation Update With 7 Day Price Move • May 11
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹127, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 380% over the past three years. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improved over the past week After last week's 18% share price gain to ₹157, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 395% over the past three years. Board Change • Mar 29
High number of new directors Additional Non-Executive Independent Director Dhara Shah was the last director to join the board, commencing their role in 2021. Valuation Update With 7 Day Price Move • Jan 27
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹190, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 682% over the past three years. Reported Earnings • Jan 21
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹2.11 (up from ₹0.80 loss in 3Q 2021). Revenue: ₹359.8m (up 34% from 3Q 2021). Net income: ₹60.9m (up ₹83.5m from 3Q 2021). Profit margin: 17% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 108% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 28% share price gain to ₹221, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 625% over the past three years. Board Change • Dec 06
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive Independent Director Dhara Shah was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improved over the past week After last week's 28% share price gain to ₹172, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 495% over the past three years. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improved over the past week After last week's 18% share price gain to ₹120, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 276% over the past three years. Reported Earnings • Nov 01
Second quarter 2022 earnings released: EPS ₹9.90 (vs ₹2.01 loss in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹745.7m (up 327% from 2Q 2021). Net income: ₹284.3m (up ₹341.8m from 2Q 2021). Profit margin: 38% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Valuation Update With 7 Day Price Move • Oct 21
Investor sentiment improved over the past week After last week's 18% share price gain to ₹93.50, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 183% over the past three years. Valuation Update With 7 Day Price Move • Sep 15
Investor sentiment improved over the past week After last week's 16% share price gain to ₹83.10, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 98% over the past three years. Board Change • Sep 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive Independent Director Dhara Shah was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment deteriorated over the past week After last week's 21% share price decline to ₹77.75, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 102% over the past three years. Reported Earnings • Jul 10
Full year 2021 earnings released: ₹4.07 loss per share (vs ₹21.29 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: ₹685.1m (up 21% from FY 2020). Net loss: ₹116.6m (loss narrowed 81% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Reported Earnings • Jun 03
Full year 2021 earnings released: ₹4.07 loss per share (vs ₹21.29 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: ₹878.1m (up 55% from FY 2020). Net loss: ₹115.5m (loss narrowed 81% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Reported Earnings • Feb 12
Third quarter 2021 earnings released: ₹0.80 loss per share (vs ₹14.50 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: ₹271.0m (up 41% from 3Q 2020). Net loss: ₹22.7m (loss narrowed 95% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 28
New 90-day high: ₹25.60 The company is up 33% from its price of ₹19.25 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Reported Earnings • Nov 07
Second quarter 2021 earnings released: ₹2.01 loss per share The company reported a soft second quarter result with increased losses and weaker control over expenses, although revenues were improved. Second quarter 2021 results: Revenue: ₹178.2m (up 28% from 2Q 2020). Net loss: ₹57.5m (loss widened 80% from 2Q 2020). 
